Rapid Cycling Bipolar Disorder: Definition, Course, and Treatment
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Rapid cycling bipolar disorder describes a course of bipolar illness in which a person experiences at least four distinct qualifying mood episodes within a 12-month period. The episodes may be manic, hypomanic, or major depressive, in a sequence that varies considerably between individuals. Rapid cycling is a diagnostic course specifier, not a separate disease, a synonym for everyday emotional changes, or proof that someone must alternate between happiness and sadness every few hours. Its clinical significance lies in the burden of recurrence, the need to examine the longitudinal pattern carefully, and the possibility that treatment and relapse prevention require particularly close review. The National Institute of Mental Health describes the four-episode threshold, while the NICE bipolar disorder guideline explains how rapid cycling fits within bipolar care.
The most important practical question is whether repeated experiences are distinct, clinically significant mood episodes that meet recognized criteria. A person can have persistent depression, shifting anxiety, sleep disturbance, medication side effects, or intensely reactive emotions without fulfilling the criteria for rapid cycling. Conversely, someone who has several adequately documented episodes during one year may qualify for the specifier even when long periods of apparent stability occur between them. A clinical assessment has to reconstruct these periods over time, ideally using treatment records and collateral history where appropriate.
For additional clinical context, see Bipolar Disorder: Symptoms, Types, Diagnosis, and Treatment, Bipolar Disorder With Mixed Features: Symptoms, Risks, and Diagnosis and Psychotic Symptoms in Bipolar Disorder: Recognition and Clinical Care.
What is rapid cycling bipolar disorder?
In the DSM framework, the rapid-cycling specifier indicates at least four mood episodes in the preceding 12 months in a person with a bipolar disorder. Qualifying episodes involve mania, hypomania, or major depression. Separate episodes are distinguished either by a switch in polarity—such as depression followed by mania or hypomania—or by at least two months of partial or full remission between episodes of the same polarity. Each counted episode must meet the relevant symptom and duration requirements, with appropriate attention to hospitalization-related criteria for mania. This longitudinal definition is set out in the clinical literature, including Chakrabarti and colleagues' 2023 review, and is consistent with the general diagnostic distinctions described by NIMH.
Rapid cycling can occur in bipolar I disorder or bipolar II disorder. Bipolar I involves at least one manic episode; bipolar II involves hypomania and major depressive episodes without a history of mania. Hypomania is not interchangeable with mania: it differs in duration, severity, and the level of impairment and may be less readily recognized by the affected person. Bipolar II is not simply a mild version of bipolar I, particularly when recurring depression creates substantial impairment. Rapid cycling describes the frequency of episodes within these diagnoses rather than replacing the underlying diagnosis. NIMH's description of bipolar types supplies the broader clinical distinctions.
The word "rapid" can be misleading. Four episodes over one year could mean several weeks of mania or depression followed by meaningful intervals of remission, not four mood changes in a day. The specifier captures a pattern of recurrent episodes, not the speed of moment-to-moment emotional reactions.
How the four-episode rule works
To understand the threshold, consider a hypothetical person with a documented major depressive episode early in the year, a subsequent hypomanic episode, a later major depressive episode, and a further manic or hypomanic episode within the same rolling 12-month window. If the episodes satisfy the applicable diagnostic criteria and are appropriately separated, that course may meet the rapid-cycling specifier. The person needs a proper bipolar diagnosis first; counting feelings on a calendar cannot establish it.
Now consider another person who wakes up distressed, feels energetic in the afternoon, becomes irritable in the evening, and experiences the same shifting pattern for several days. These changes deserve attention when distressing or impairing, but they do not automatically amount to several hypomanic, manic, and depressive episodes. A mood diary records experience; clinical assessment determines whether the pattern represents syndromal episodes.
The 12-month interval can be evaluated at different points in a person's course. Having rapid cycling during one period does not prove that the pattern will continue throughout life. In a 2023 study of 1,261 patients, the majority of people with a history of rapid cycling had prospective recurrence rates below four episodes a year, illustrating how the course specifier can change over time. A single retrospective report of numerous episodes also requires examination of dates, episode boundaries, treatments, and diagnostic uncertainty.
Mania, hypomania, depression, and mixed features
Mania involves a distinct period of elevated, expansive, or irritable mood with increased activity or energy and associated changes such as markedly reduced need for sleep, increased speech, racing thoughts, distractibility, grandiosity, or risky behavior. The episode produces marked impairment, requires hospitalization in some cases, or involves psychotic features. Hypomania shares a recognizable activation pattern but is less severe and does not meet the impairment, hospitalization, or psychosis threshold for mania. The NIMH bipolar disorder overview explains these characteristic changes and distinctions.
Major depressive episodes involve a sustained cluster of depressive symptoms, often including depressed mood or loss of interest, alterations in sleep and appetite, impaired concentration, feelings of worthlessness, and sometimes suicidal thinking. In bipolar disorder, major depressive episodes can consume more time and impose more disability than elevated-mood episodes. A history of depression alone does not establish bipolar disorder; the longitudinal assessment must identify qualifying manic or hypomanic episodes as applicable to the diagnosis. NICE CG185 recommends a detailed history of mood, activity, disinhibition, functioning, relapse patterns, and treatment response.
Mixed features describe symptoms of the opposite polarity occurring during an otherwise identifiable manic, hypomanic, or depressive episode. The presence of agitation, insomnia, or irritability alone is insufficient to assign a mixed-features specifier. Mixed presentations can complicate risk assessment and treatment selection; they should be documented as features of qualifying episodes rather than casually counted as additional discrete episodes. Clinical treatment recommendations differ according to the actual phase and presentation, as described in the CANMAT/ISBD 2023 evidence update.
Is rapid cycling the same as mood swings every day?
No. Everyday mood fluctuations, rapid emotional reactivity, and clinically defined bipolar episodes operate on different time scales and may have different causes. Emotional states can shift within hours because of events, interpersonal conflict, pain, stress, medications, or sleep deprivation. These changes can coexist with a bipolar disorder, but the rapid-cycling specifier concerns the number of qualifying episodes during a year.
The terms "ultra-rapid cycling" and "ultradian cycling" appear in research and some clinical discussions for changes over days or within a day. They are inconsistently defined, are not separate standard DSM diagnostic categories, and cannot automatically be treated as multiple full-duration episodes. The 2023 rapid-cycling review discusses these terms and the gaps in evidence. When mood and energy change many times in one day, clinicians examine the complete symptom pattern, triggers, sleep, substance exposure, baseline temperament, and differential diagnoses.
How common is rapid cycling?
Frequency estimates depend strongly on how and when patients are sampled, whether the study uses lifetime history or a defined recent 12-month period, and whether the sample comes from specialized care. It would be misleading to give one percentage as the prevalence in all people with bipolar disorder. For example, Miola and colleagues identified a history of at least one rapid-cycling year in 9.36% of a clinical cohort of 1,261 people, with differing proportions in bipolar I and II. This is a result in a particular cohort, not a general-population prevalence estimate.
Clinic-based samples and studies of different time windows can yield higher figures. The appropriate inference is that rapid cycling is an established and clinically important course pattern within bipolar disorder, while the proportion affected and the stability of the pattern vary across study designs and populations.
What causes rapid cycling?
Rapid cycling has no single proven cause. Bipolar disorders arise from interacting genetic, neurobiological, behavioral, environmental, and clinical influences. The more specific question is which factors are associated with a higher frequency of mood episodes, which can precipitate relapses in an individual, and which are potentially modifiable without assuming they caused the illness.
Clinical studies have examined thyroid dysfunction, antidepressant exposure, sleep-wake and circadian disruption, substance use, illness history, and treatment adherence. Associations require careful interpretation. A finding that people with rapid cycling are more likely to have a particular exposure does not prove that the exposure caused rapid cycling; sicker patients may receive more treatments, and the relationship may run in both directions. Miola and colleagues' longitudinal analysis illustrates these distinctions between association and subsequent course.
Thyroid function and medical contributors
Thyroid disease can influence mood and energy and should be considered in the broader evaluation of recurrent episodes, particularly in people taking lithium. An earlier prospective study identified thyroid abnormalities in a small rapid-cycling clinical sample, but its design and size do not establish thyroid dysfunction as the cause of all rapid cycling. See Bauer, Whybrow, and Winokur and NICE guidance on renal and thyroid monitoring. Evaluation may also consider other medical conditions and medications that can mimic or intensify mood symptoms.
Sleep and circadian rhythms
Changes in sleep can be an early warning sign, a consequence of an episode, and a contributor to instability. Reduced need for sleep during mania or hypomania is clinically different from being exhausted but unable to sleep. Irregular shift work, major time-zone changes, disrupted routines, or sustained sleep deprivation merit attention in a relapse-prevention plan. The 2023 VA/DoD guideline addresses the clinical assessment and ongoing management of bipolar episodes; sleep and routine measures are adjuncts to indicated treatment, not substitutes for it.
Antidepressants and treatment-emergent changes
Antidepressants deserve individualized review when someone develops repeated activation, mixed symptoms, or apparent treatment-emergent mood switching. A secondary analysis of a relatively small randomized STEP-BD trial found worse long-term outcomes among participants with rapid cycling who continued antidepressants after recovery from bipolar depression. Because the subgroup was small, the finding informs caution rather than proving a universal causal rule or mandating abrupt discontinuation. See El-Mallakh and colleagues' rapid-cycling analysis. The CANMAT/ISBD guideline summary advises avoiding or carefully considering antidepressants in the presence of recent rapid cycling or mixed features and recommends against antidepressant monotherapy for bipolar I depression. Medication changes require a prescribing clinician's supervision.
Does rapid cycling get worse over time?
A rapid-cycling year may be associated with substantial illness burden, frequent depression, functional interruption, and increased need for monitoring. It is a clinically useful sign of recurrence, but it is not a deterministic prediction of lifelong worsening. The long-term pattern can change and, for some people, episode frequency falls below the threshold. In the 2023 cohort analysis, historical rapid cycling often did not remain rapid cycling during prospective follow-up.
Outcome depends on the underlying bipolar condition, the types and severity of episodes, coexisting conditions, effective treatment, physical health, stressors, substance use, and continuity of care. It is therefore more informative to ask whether a person's actual recurrence frequency, symptom burden, functioning, and risk are improving than to treat the label as a permanent identity.
How clinicians assess and diagnose rapid cycling
A psychiatrist or other appropriately trained clinician first evaluates whether the person meets criteria for a bipolar disorder, identifies its type, and then reconstructs episodes within a 12-month interval. The assessment explores symptoms, duration, severity, observable changes in activity and energy, impairment, hospitalization, psychosis, suicidality, and whether periods of apparent recovery truly separate episodes. NICE CG185 recommends recording episode history, relapse patterns, functional effects, medical and psychiatric comorbidity, treatment response, and collateral observations when the patient agrees.
A useful clinical timeline records approximate onset and end dates, whether episodes were depressive, manic, or hypomanic, what happened to sleep and functioning, and which treatments or other exposures coincided with the changes. Clinical notes, prescriptions, hospital discharge records, and observations from trusted people may clarify episodes that were difficult to recognize at the time. Diaries or apps can support reconstruction, but their graphs and scores do not diagnose bipolar disorder or independently prove the four-episode rule.
Screening questionnaires may prompt further conversation in some services; a positive score cannot establish the diagnosis, identify all episode boundaries, or rule out other causes. Clinicians may use structured interviews or rating scales to support a more complete assessment. The VA/DoD 2023 guideline places diagnosis and triage within a broader treatment process.
What can look like rapid cycling?
The differential diagnosis starts with the timeline. Unipolar depressive disorders can involve repeated depression without mania or hypomania. Borderline personality disorder may involve marked interpersonal and emotional reactivity that can occur on a different time scale from syndromal bipolar episodes. ADHD may involve enduring attentional or activity patterns rather than new episodes. Anxiety, obsessive-compulsive disorder, trauma-related symptoms, sleep disorders, substance effects, medications, and thyroid dysfunction can contribute to mood variability. Coexisting conditions are possible, so identifying one does not automatically exclude another. NICE's clinical assessment guidance explicitly includes these diagnostic possibilities.
A person with persistent depressed mood and occasional brief periods of restlessness may require a different assessment from someone with clearly documented episodes of hypomania and depression. Psychotic symptoms also need their own careful temporal assessment: psychosis occurring during a manic or depressive episode does not by itself constitute a separate cycle. These distinctions protect both diagnostic accuracy and treatment planning.
Treatment: is there a special medication for rapid cycling?
There is no single universally established rapid-cycling-specific medication algorithm. The key clinical principle is to treat the actual bipolar phase—acute mania or hypomania, bipolar depression, and prevention of further episodes—while reviewing recurrence, treatment response, adverse effects, comorbidity, and adherence. NICE recommendation 1.1.3 specifically advises using the same interventions offered for other bipolar presentations because strong evidence for a different rapid-cycling pathway is lacking. The VA/DoD 2023 guideline and CANMAT/ISBD evidence update distinguish acute phases and maintenance.
This distinction matters because a medication supported for acute mania may have different evidence for bipolar depression or for preventing future episodes. A trial that improves depressive symptoms over eight weeks cannot alone establish that the treatment prevents rapid cycling for years. Likewise, the absence of success with one medication does not prove that all approaches will fail.
Acute mania or severe activation
When a person is experiencing mania, clinical priorities include reducing acute symptoms, evaluating psychosis and judgment, protecting sleep, and deciding whether urgent specialist or hospital care is required. Evidence-based options can include antipsychotics and mood-stabilizing medicines selected according to the person's history and safety profile. NICE's acute mania recommendations list specific options and explain when medication combinations or urgent interventions may be needed.
Bipolar depression
Depression is often prominent in recurrent bipolar illness and needs active treatment rather than assuming all episodes are elevated mood. Guidelines identify phase-specific options that can include quetiapine, lithium, lamotrigine, and other selected medicines or combinations, depending on the diagnosis and clinical circumstances. In a small randomized eight-week subgroup analysis, quetiapine improved depressive symptoms in patients with bipolar I or II disorder and a rapid-cycling course compared with placebo. This supports short-term antidepressant efficacy for that study population, not a claim that every person with rapid cycling should receive quetiapine or that it is proven superior for long-term cycling prevention.
Long-term maintenance and recurrence prevention
Maintenance treatment aims to reduce future episodes, sustain functioning, and monitor safety over time. Lithium is a major evidence-based maintenance option in bipolar disorder, although the relative benefit of different agents in exclusively rapid-cycling samples remains uncertain. An older 20-month randomized trial comparing lithium with divalproex in a narrowly selected stabilized rapid-cycling group did not demonstrate a significant advantage for divalproex. Substantial attrition and a small randomized sample limit the conclusions that can be drawn. More general bipolar maintenance trials cannot be assumed to answer every rapid-cycling-specific question.
When symptoms continue, clinicians may reassess the diagnosis, episode polarity, adherence, serum levels when appropriate, sleep, interactions, medical contributors, and coexisting disorders. A change in medication or a combination treatment is based on the whole clinical picture rather than on the episode count alone.
Medication safety and monitoring
Lithium
Lithium requires planned blood-level monitoring because the effective range and toxic range are relatively close, as well as monitoring of kidney function, thyroid function, electrolytes, and other relevant health measures. Dehydration, acute illness, changes in sodium balance, and interacting medications can raise safety concerns. A person taking lithium who develops significant vomiting, diarrhea, marked tremor, confusion, or unsteadiness needs prompt medical assessment for possible toxicity. Clinicians and patients should agree on an individualized monitoring and sick-day plan. NICE guidance on prescribing and monitoring lithium describes the required surveillance and cautions against rapid discontinuation.
Lamotrigine
Lamotrigine is used for selected bipolar indications, particularly in relation to depressive recurrence, and is not an acute antimanic treatment. It requires slow titration because serious rash, including potentially life-threatening skin reactions, can occur. Its interaction with valproate is especially important. A new rash or other concerning reaction during lamotrigine treatment requires immediate professional advice; urgent care is appropriate for severe rash, blistering, mucosal involvement, or systemic illness. NICE's lamotrigine recommendations distinguish it from acute mania treatment and address titration and interactions.
Valproate or divalproex
Valproate can have a role in selected bipolar presentations, but it carries serious fetal and developmental risks during pregnancy and requires careful consideration of reproductive plans, effective contraception where applicable, drug interactions, liver function, blood counts, weight, and adverse effects. Requirements and prescribing restrictions vary by jurisdiction. Patients who are pregnant, planning pregnancy, or could become pregnant need prompt specialist review of their treatment plan, while also avoiding abrupt self-directed discontinuation. NICE CG185 incorporates extensive medication safety precautions and reproductive-risk guidance.
Antipsychotics
Some antipsychotics have evidence for acute mania, some for bipolar depression, and some for maintenance; their roles differ by drug, phase, and patient. Monitoring can include weight, glucose or HbA1c, lipid profile, blood pressure, movement-related effects, sedation, and cardiovascular risks according to the medication and medical history. Sedation or metabolic adverse effects can affect daily functioning and continued use. NICE's monitoring recommendations and CANMAT/ISBD recommendations support individualized balancing of benefits and harms.
Antidepressants
Antidepressant treatment in bipolar disorder requires particular attention to emerging mania or hypomania, mixed symptoms, and the history of rapid cycling. Treatment decisions should distinguish bipolar I from bipolar II, assess accompanying mood-stabilizing treatment, and consider the relevant evidence. The CANMAT/ISBD update calls for caution with recent rapid cycling. A person should discuss concerns or early activation with the prescriber promptly rather than independently starting, stopping, or changing doses.
Psychotherapy, family support, and everyday recovery
Evidence-based psychotherapy can contribute to relapse prevention, shared understanding of episodes, recognition of warning signs, medication collaboration, family communication, and coping with the consequences of illness. Approaches developed for bipolar disorder include psychoeducation, cognitive behavioral strategies, family-focused work, and interventions addressing social and sleep-wake routines. For bipolar disorder overall, psychological therapies used alongside appropriate psychiatric care can improve some outcomes, although effects vary by approach and the population studied. See the systematic review by Lam and colleagues and the NICE long-term care recommendations.
The specific evidence base for people already meeting the rapid-cycling specifier is much thinner. A 2023 review of adjunctive nonpharmacological treatment found possible benefits for several interventions but judged the rapid-cycling-specific evidence to be limited and methodologically weak. Its findings do not justify promising that any one form of psychotherapy or lifestyle intervention will stop repeated episodes. Electroconvulsive therapy may be considered by specialist teams for selected severe, urgent, or treatment-resistant presentations; this is not routine care for every person with rapid cycling.
A practical recovery plan typically identifies the person's own earliest episode indicators, sleep and routine changes, clinical contacts, circumstances requiring urgent review, realistic occupational adjustments, and how trusted supporters can help if the person wishes. For some, the first signs are reduced need for sleep, unusually fast plans, rapid speech, or spending changes; for others, declining energy, withdrawal, loss of interest, and suicidal thoughts require attention. Tracking should focus on meaningful patterns without promoting constant self-surveillance.
What families and partners can do
Family members and partners can support accurate assessment by describing observable changes and their timing, if the person agrees, and by participating in a shared relapse plan. They can also help reduce avoidable conflict over interpretation: a single disagreement or excited afternoon is not automatically a manic episode, and a period of quiet is not necessarily recovery from depression. It is more useful to ask about sustained changes in sleep, functioning, judgment, communication, and safety.
Supporters also have their own needs, including information, appropriate boundaries, and access to caregiver support. NICE CG185 recommends information and support for carers and considers the practical effects of bipolar episodes on work, finances, and relationships.
When rapid cycling needs urgent help
Urgent evaluation is appropriate when mania is accompanied by dangerous decisions, profound loss of sleep, escalating agitation, inability to care for oneself, psychosis, or behavior that threatens safety; likewise, severe depression with suicidal thoughts, intent, or an inability to remain safe requires prompt help. The NICE guideline recommends urgent specialist assessment when mania or severe depression is suspected or there is danger to the individual or others.
If there is an immediate threat to life or safety, contact local emergency services or attend the nearest emergency department. In the United States, people in emotional crisis or with suicidal thoughts can call or text 988; elsewhere, use locally available crisis and emergency services. For emerging but non-immediate warning signs, contact the treating team promptly, share the symptom timeline, and follow an established crisis plan where available.
Rapid cycling during pregnancy, adolescence, and later life
Pregnancy and the postpartum period can alter relapse risk, medication safety, sleep, and the urgency of assessing new symptoms. A reproductive-age patient taking lithium, valproate, or other psychiatric medication needs individualized specialist counseling before conception and coordinated care during pregnancy or after delivery. Evidence and medication restrictions in pregnancy are distinct from the usual adult trial literature. The NICE bipolar guideline directs readers to specialized antenatal and postnatal mental-health guidance.
For children and adolescents, diagnostic assessment must take developmental stage, episode duration, functional change, family history, and alternative explanations into account. Pediatric symptoms and treatment evidence should not be interpreted using adult rapid-cycling assumptions alone. In older adults, consider neurological or medical contributors, multiple medications, changes in renal function, and susceptibility to adverse effects. A history of bipolar disorder remains relevant, but new-onset activation calls for careful medical review.
Common misconceptions about rapid cycling
The phrase does not mean that someone has four emotions a year, four emotional outbursts in a week, or a personality that changes rapidly. It refers to qualifying mood episodes within an established bipolar course. Nor does the count determine the individual's treatment by itself; episode polarity, severity, safety, previous response, and side effects remain central. NIMH describes rapid cycling as an episode-frequency feature, and NICE does not recommend a separate generic treatment pathway simply because of the specifier.
A history of rapid cycling also does not mean that stability is impossible. Prospective clinical data show that people can move below the four-episode threshold, even though ongoing recurrence remains an important concern. A change in the label should be evaluated alongside the person's actual symptoms and functional recovery. See the 2023 longitudinal cohort study.
Frequently asked questions
Can you have rapid cycling bipolar II disorder?
Yes. The rapid-cycling course specifier can apply to bipolar II disorder when at least four qualifying hypomanic or major depressive episodes occur in a 12-month interval and the appropriate separation criteria are satisfied. It does not convert hypomania into mania. NIMH's bipolar types guide distinguishes the conditions.
Can rapid cycling occur without mania?
A person with bipolar II disorder may meet the rapid-cycling specifier without ever having a manic episode, because hypomanic and major depressive episodes can qualify. The underlying bipolar diagnosis still must be established. Repeated depressive episodes without hypomania or mania do not themselves demonstrate bipolar rapid cycling.
Does rapid cycling mean cycling every 24 hours?
No. The DSM rapid-cycling specifier uses at least four separate qualifying episodes during 12 months. Terms such as ultradian cycling have appeared in research for within-day shifts, but they do not replace the formal episode criteria. Chakrabarti and colleagues discuss the separate terminology.
How many mood episodes must a person have?
At least four qualifying manic, hypomanic, or major depressive episodes in a rolling 12-month period, with the appropriate diagnostic duration and separation requirements. A self-recorded emotional change is useful information, but it is not automatically an episode.
Can rapid cycling stop?
The course can change. Rapid cycling may be present during one observed year and absent later, though the underlying bipolar disorder may still require ongoing treatment and relapse prevention. The 2023 prospective cohort findings support the importance of monitoring actual recurrence rather than assuming the specifier is permanent.
Is lithium ineffective in rapid cycling?
That conclusion is unsupported. Lithium is an established treatment option in bipolar disorder, but studies restricted to rapid cycling are limited and sometimes have substantial attrition. A randomized study comparing lithium and divalproex did not find a significant advantage for divalproex, which does not mean either drug works for every patient. See Calabrese and colleagues and the NICE maintenance guideline.
Should antidepressants always be stopped?
Medication decisions require individualized clinical assessment. Recent rapid cycling, mixed symptoms, or treatment-emergent mania justify careful review, and antidepressant monotherapy is not recommended for bipolar I depression. Abrupt self-directed changes may cause harm. Discuss any change and the safest method of adjustment with the prescriber. See the CANMAT/ISBD guidance.
How should I prepare for a clinical appointment?
Bring a calendar of major changes in mood, energy, and sleep; approximate dates and durations; medication history; hospital or emergency visits; changes in functioning; and any information a trusted person can provide with your agreement. Report suicidal thoughts, unusually risky behavior, marked reductions in the need for sleep, or possible medication toxicity promptly. Ask the clinician to clarify which experiences count as full episodes, how the bipolar type was determined, and how the treatment plan addresses both acute phases and recurrence.
Related Articles
References
Bauer, M. S., Whybrow, P. C., & Winokur, A. (1990). Rapid cycling bipolar affective disorder. I. Association with grade I hypothyroidism. Archives of General Psychiatry, 47(5), 427–432. DOI.
Calabrese, J. R., et al. (2005). A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. American Journal of Psychiatry, 162(11), 2152–2161. DOI.
Chakrabarti, S., Jolly, A. J., Singh, P., & Yadhav, N. (2023). Role of adjunctive nonpharmacological strategies for treatment of rapid-cycling bipolar disorder. World Journal of Psychiatry, 13(8), 495–510. DOI.
El-Mallakh, R. S., et al. (2015). Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial. Journal of Affective Disorders, 184, 318–321. PubMed.
Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. Focus, 21(4), 344–353. DOI.
Lam, D. H., et al. (2009). Psychological therapies in bipolar disorder: The effect of illness history on relapse prevention—a systematic review. Bipolar Disorders. PubMed.
Miola, A., Tondo, L., Pinna, M., Contu, M., & Baldessarini, R. J. (2023). Characteristics of rapid cycling in 1261 bipolar disorder patients. International Journal of Bipolar Disorders, 11, 21. DOI.
National Institute for Health and Care Excellence. (2014; current recommendations updated subsequently). Bipolar disorder: Assessment and management (CG185). Official guideline.
National Institute of Mental Health. (n.d.). Bipolar disorder. Official clinical overview.
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for the management of bipolar disorder. Official guideline.
Vieta, E., Calabrese, J. R., Goikolea, J. M., Raines, S., & Macfadden, W. (2007). Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: A randomized, double-blind, placebo-controlled study. Bipolar Disorders, 9(4), 413–425. DOI.